Advertisement

18FDG-PET/CT Imaging in Breast Cancer Patients with Clinical Stage IIB or Higher

Commentary on “Overuse of Preoperative Staging of Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer” by Marissa K. Srour et al.
  • David GroheuxEmail author
  • Elif Hindié
Breast Oncology

Notes

Disclosure

David Groheux and Elif Hindié declare no conflicts of interest.

References

  1. 1.
    Srour MK, Lee M, Walcott-Sapp S, Luu M, Chung A, Giuliano AE, et al. Overuse of preoperative staging of patients undergoing neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2019;26:3289–94.CrossRefGoogle Scholar
  2. 2.
    Groheux D, Hindié E, Delord M, Giacchetti S, Hamy A-S, de Bazelaire C, et al. Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104:1879–87.CrossRefGoogle Scholar
  3. 3.
    Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J. 2010;16:617–24.CrossRefGoogle Scholar
  4. 4.
    Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, et al. 18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2016;43:1937–44.CrossRefGoogle Scholar
  5. 5.
    Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA. 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging. 2017;44:1420–7.CrossRefGoogle Scholar
  6. 6.
    Ulaner GA. PET/CT for patients with breast cancer: where is the clinical impact? AJR Am J Roentgenol. 2019;213:254–65.CrossRefGoogle Scholar
  7. 7.
    Lebon V, Alberini J-L, Pierga J-Y, Diéras V, Jehanno N, Wartski M. Rate of distant metastases on 18F-FDG PET/CT at initial staging of breast cancer: comparison of women younger and older than 40 years. J Nucl Med. 2017;58:252–7.CrossRefGoogle Scholar
  8. 8.
    Groheux D, Giacchetti S, Delord M, Hindié E, Vercellino L, Cuvier C, et al. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med. 2013;54:5–11.CrossRefGoogle Scholar
  9. 9.
    Salaün P-Y, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47(1):28–50.  https://doi.org/10.1007/s00259-019-04553-8.CrossRefPubMedGoogle Scholar
  10. 10.
    Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2020

Authors and Affiliations

  1. 1.Department of Nuclear Medicine, Service de Médecine NucléaireSaint-Louis HospitalParis Cedex 10France
  2. 2.Department of Nuclear MedicineBordeaux University HospitalBordeauxFrance

Personalised recommendations